Understand the source comparison
Klow Compare to Other Research Peptides: Comparison
Klow (KPV) NF-κB translocation inhibition. Blocks inflammatory cytokine transcription at the nuclear level Inflammatory bowel disease models, chronic dermatitis, psoriasis, autoimmune inflammation, colitis 4–6 hours (subcutaneous) Twice daily Synergizes with B
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Klow (KPV)
- NF-κB translocation inhibition. Blocks inflammatory cytokine transcription at the nuclear level
- Inflammatory bowel disease models, chronic dermatitis, psoriasis, autoimmune inflammation, colitis
- 4–6 hours (subcutaneous)
- Twice daily
- Synergizes with BPC-157 for tissue repair in inflammatory environments; with TB-500 when migration must occur without inflammation
- Klow is the only peptide that selectively inhibits inflammatory gene expression without immunosuppression. Irreplaceable when localized inflammation control is the research goal
- BPC-157
- VEGF and FGF upregulation. Drives angiogenesis, fibroblast proliferation, and collagen synthesis
- Tendon repair, gastric ulcer healing, ligament injury, post-surgical recovery, vascular injury models
- 4–6 hours (systemic distribution)
- Once or twice daily
- Works best with Klow in chronic inflammatory wounds where tissue synthesis is slowed by cytokine activity
- Best choice when the rate-limiting factor is vascular supply and collagen deposition. Not inflammation control
- TB-500
- Actin polymerization and MMP upregulation. Promotes cell migration, differentiation, and tissue remodeling
- Myocardial infarction, stroke models, large tissue trauma, corneal injury, skeletal muscle regeneration
- 10 days (circulation)
- Twice weekly
- Pairs with Klow when cell migration into inflamed tissue is required. TB-500 drives migration, Klow prevents apoptosis at arrival
- Ideal for models where cellular infiltration and migration are limiting factors. Less effective when inflammation is the problem
- Melanotan II
- MC1R and MC4R agonism. Induces melanogenesis, reduces appetite, modulates libido (off-target effects in inflammation research)
- Photoprotection studies, metabolic research, melanocyte activation models
- 1–2 hours (rapid clearance)
- Multiple daily doses
- Not typically combined with anti-inflammatory peptides; mechanism overlaps minimally with Klow despite structural similarity to α-MSH
- Not an anti-inflammatory agent despite α-MSH lineage. Researched primarily for melanocyte and metabolic pathways
- Selank
- Monoamine modulation and BDNF upregulation. Anxiolytic and nootropic effects through GABAergic and serotonergic pathways
- Anxiety models, cognitive function studies, stress response research, neuroinflammation (secondary effects)
- 15–20 minutes (rapid degradation)
- 2–3 times daily (intranasal preferred)
- Minimal overlap with Klow. Works centrally on neurotransmission rather than peripheral inflammation
- Mechanistically unrelated to Klow; included here because both derive from endogenous regulatory peptides but address completely different systems